Lexaria Bioscience Corp - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
LEXX Nasdaq 2833 https://www.lexariabioscience.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexaria Bioscience Corp

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space - May 26th, 2022 12:30 pm
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space - May 25th, 2022 12:30 pm
Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs - Apr 21st, 2022 2:39 pm
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs - Apr 21st, 2022 1:05 pm
LEXX: Hypertension Results Raise Stakes - Apr 19th, 2022 3:38 pm
Lexaria Commences Multi-Week Human Clinical Hypertension Study - Apr 19th, 2022 1:05 pm
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results - Apr 14th, 2022 12:45 pm
Lexaria Provides Update on Human Nicotine Study NIC-H22-1 - Apr 12th, 2022 1:10 pm
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program - Apr 11th, 2022 1:00 pm
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program - Mar 15th, 2022 6:05 pm
Lexaria Granted Important New Oral Nicotine Patent - Mar 8th, 2022 2:15 pm
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study - Feb 2nd, 2022 2:25 pm
LEXX: 1Q:22 Results & Other Things that Came Up - Feb 2nd, 2022 11:38 am
Lexaria Provides Annual Letter From the CEO - Jan 27th, 2022 2:35 pm
IBN (InvestorBrandNetwork) Announces EDGE Podcast Interview with Lexaria Bioscience Corp. CEO Chris Bunka - Jan 20th, 2022 1:00 pm
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2 - Jan 18th, 2022 2:25 pm
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4 - Dec 29th, 2021 4:15 pm
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc. - Dec 16th, 2021 7:45 pm
LEXX: An R&D Extravaganza - Dec 16th, 2021 4:33 pm
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion - Dec 14th, 2021 4:50 pm